Health & Medicine

STAT+: FDA wants to exclude weight-loss drugs from a compounding list

24 sec read0 views0 listens

The FDA has proposed excluding semaglutide and tirzepatide from a list of substances for compounding, deeming no clinical need for large-scale production by 503B facilities. This move impacts developers and tech professionals in pharmaceuticals by limiting the availability of compounded versions of popular weight-loss and diabetes drugs, potentially steering innovation towards new treatments.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Tech & Gadgets12 hours ago25 sec read

How Toronto is using Clariti's AI to speed up building permit approvals

Toronto has launched a one-year pilot program with Clariti's CivCheck AI software to expedite the city's building permit approval process. This initiative aims to reduce delays caused by incomplete applications, which can add significant costs for de...

Ali Nemati

Biotech & Pharma15 hours ago28 sec read

CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial

A Phase 1 clinical trial at Charité—Universitätsmedizin Berlin has shown that CAR T-cell therapy significantly reduced disease activity in six patients with severe, treatment-refractory rheumatoid arthritis (RA), with three achieving sustained remiss...

Ali Nemati

Biotech & Pharma20 hours ago26 sec read

STAT+: Pharmalittle: We're reading about an AstraZeneca trial failure, a 'monstrous' conflict of interest, and more

AstraZeneca's heart disease trial for its experimental drug failed, showing no additional benefits for patients already on stabilizer drugs. This setback highlights challenges in a competitive market and underscores the difficulty of improving outcom...

Ali Nemati